Science & technology | Treating dementia
A drug for Alzheimer’s disease that seems to work
It is not perfect. And it has side-effects. But it may be the real deal
Editor’s note: On January 6th America’s Food and Drug Administration approved lecanemab, to be marketed as Leqembi.
This article appeared in the Science & technology section of the print edition under the headline “Enter lecanemab”
From the December 3rd 2022 edition
Discover stories from this section and more in the list of contents
Explore the edition
Satellites are polluting the stratosphere
And forthcoming mega-constellations will exacerbate the problem
AI models are dreaming up the materials of the future
Better batteries, cleaner bioplastics and more powerful semiconductors await
Mice have been genetically engineered to look like mammoths
They are small and tuskless, but extremely fluffy
Is posh moisturiser worth the money?
Don’t break the bank
How artificial intelligence can make board games better
It can iron out glitches in the rules before they go on the market
The skyrocketing demand for minerals will require new technologies
Flexible drills, distributed power systems and, of course, artificial intelligence